Long-term Maintenance Study of Aripiprazole in the Treatment of Irritability Associated With Autistic Disorder
Aripiprazols sikkerhed og effekt i langsigtet vedligeholdelsesbehandling af pædiatriske patienter med irritabilitet forbundet med autistisk lidelse
The purpose of this study is to determine whether pediatric participants with irritability associated with autistic disorder who have responded to aripiprazole treatment will experience a relapse significantly later when continuing therapy with aripiprazole than will participants who receive placebo.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 4
Kontakter og lokationer
Studiesteder
-
-
Alabama
-
Dothan, Alabama, Forenede Stater, 36303
- Harmonex Neuroscience Research, Inc
-
-
Arizona
-
Phoenix, Arizona, Forenede Stater, 85006
- Southwest Autism Research And Resource Center
-
-
California
-
Costa Mesa, California, Forenede Stater, 92626
- Clinical Innovations, Inc.
-
Glendale, California, Forenede Stater, 91206
- Behavioral Research Specialists, Llc
-
Palo Alto, California, Forenede Stater, 94306
- Abbey Neuropsychology Clinic
-
San Francisco, California, Forenede Stater, 94143
- Ucsf - Lppi
-
Stanford, California, Forenede Stater, 94305
- Stanford University School Of Medicine
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forenede Stater, 20010
- Children'S National Medical Center
-
-
Florida
-
Gainesville, Florida, Forenede Stater, 32607
- Sarkis Clinical Trials
-
Hialeah, Florida, Forenede Stater, 33012
- Palm Springs Research Institute
-
Maitland, Florida, Forenede Stater, 32751
- Florida Clinical Research Center, Llc
-
Miami, Florida, Forenede Stater, 33155
- Miami Children'S Hospital
-
Tampa, Florida, Forenede Stater, 33613
- University Of South Florida
-
-
Georgia
-
Smyrna, Georgia, Forenede Stater, 30080
- Institute For Behavioral Medicine, Llc
-
-
Idaho
-
Coeur d'Alene, Idaho, Forenede Stater, 83814
- Kootenai Behavioral Health Center
-
-
Kentucky
-
Louisville, Kentucky, Forenede Stater, 40202
- Kosair Charities Pediatric Clinical Research Unit
-
-
Louisiana
-
Shreveport, Louisiana, Forenede Stater, 71103
- Lsu Health Sciences Center
-
-
Massachusetts
-
Newton, Massachusetts, Forenede Stater, 02459
- Neurocare, Inc.
-
-
Michigan
-
Bloomfield Hills, Michigan, Forenede Stater, 48302
- Neurobehavioral Medicine Group
-
-
Nevada
-
Las Vegas, Nevada, Forenede Stater, 89128
- Center For Psychiatry And Behavioral Medicine, Inc
-
-
New Jersey
-
Gibbsboro, New Jersey, Forenede Stater, 08026
- Clinical Research Center Of New Jersey
-
Toms River, New Jersey, Forenede Stater, 08755
- Children'S Specialized Hosp
-
-
New York
-
Stony Brook, New York, Forenede Stater, 11794
- Stony Brook University School Of Medicine
-
-
North Carolina
-
Chapel Hill, North Carolina, Forenede Stater, 27517
- Unc Chapel Hill
-
-
Ohio
-
Cleveland, Ohio, Forenede Stater, 44106
- University Hospitals Case Medical Center
-
Cleveland, Ohio, Forenede Stater, 44104
- Cleveland Clinic
-
Columbus, Ohio, Forenede Stater, 43210
- The Ohio State University Nisonger Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forenede Stater, 73116
- Cutting Edge Research Group
-
Oklahoma City, Oklahoma, Forenede Stater, 73117
- Ou Physician'S Child Study Center
-
Tulsa, Oklahoma, Forenede Stater, 74104
- Tulsa Clinical Research, Llc
-
-
Oregon
-
Gresham, Oregon, Forenede Stater, 97030
- Cyn3rgy Research
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19124
- Drexel University College Of Medicine
-
Pittsburgh, Pennsylvania, Forenede Stater, 15203
- Western Psychiatric Institute And Clinic
-
-
Tennessee
-
Kingsport, Tennessee, Forenede Stater, 37660
- Holston Medical Group
-
-
Texas
-
DeSoto, Texas, Forenede Stater, 75115
- Insite Clinical Research
-
-
Utah
-
Clinton, Utah, Forenede Stater, 84015
- Ericksen Research And Development
-
-
Virginia
-
Norfolk, Virginia, Forenede Stater, 23510
- Childrens Specialty Gr., Pllc
-
Richmond, Virginia, Forenede Stater, 23298
- Virginia Treatment Center For Children
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Key Inclusion Criteria:
- Male or female children or adolescents, 6 to 17 years of age, inclusive, at the time of the baseline visit
- Meets current diagnostic criteria of the Diagnostic and Statistical Manual-of Mental Disorders IV-Text Revised for autistic disorder and displays behaviors such as tantrums, aggression, self-injurious behavior, or a combination of these problems. Diagnosis of autistic disorder will be confirmed by the Autism Diagnostic Interview-Revised.
- Participant or designated guardian or caregiver is able to comprehend and satisfactorily comply with the protocol requirements, in the opinion of the investigator.
- Demonstrates behaviors such as tantrums, aggression, or self-injury or a combination of these problems
- An Aberrant Behavior Checklist Irritability subscale score ≥18 AND a Clinical Global Impressions Severity score ≥4 at the Screening and Baseline Visits.
- Mental age of at least 24 months
Key Exclusion Criteria:
- Treatment resistant to neuroleptic medication, based on lack of therapeutic response to 2 different neuroleptics after treatment for at least 3 weeks each.
- Previous treatment with aripiprazole for at least 3 weeks duration at an adequate daily dose, without demonstrating a clinically meaningful response.
- Lifetime diagnosis of bipolar disorder, psychosis, or schizophrenia, or a current diagnosis of major depressive disorder
- Diagnosis of Pervasive Developmental Disorder-Not Otherwise Specified, Asperger's Syndrome, Rett's Syndrome, childhood disintegrative disorder, or Fragile X Syndrome
- History of neuroleptic malignant syndrome
- At significant risk for suicide based on history or routine psychiatric status examination
- A seizure within the past year
- History of severe head trauma or stroke
- History or current evidence of any unstable medical conditions that would expose the patient to undue risk of a significant adverse event or interfere with assessments of safety or efficacy during the course of the trial
- Weight lower than 15 kg
- Known allergy or hypersensitivity to aripiprazole or other dihidrocarbostyrils
- History of a clinically significant low white blood cell count or a drug-induced leukopenia/neutropenia
- Any other medically significant abnormal laboratory test or vital sign result or electrocardiogram finding
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Placebo komparator: Placebo
|
Tablets, oral, 0 mg, once daily, 16 weeks |
|
Eksperimentel: Aripiprazol
|
Tablets, oral, 2-15 mg, once daily, 13-42 weeks
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage of Patients Relapsing by Week 16
Tidsramme: From end of Phase 1 (Date of randomization) to Week 16 of Phase 2 and end of treatment
|
Time of relapse=date when patient meets relapse criteria. There are 4 definitions for relapse: 1. Patient meets the following criteria for 2 consecutive visits: (a) Aberrant Behavior Checklist Irritability score ≥25% than score at end of Phase 1 AND (b) Clinical Global Impression Improvement scale rating of 'Much Worse' or 'Very Much Worse' relative to rating at end of Phase 1. If relapse criteria met at 1 visit, 2nd visit should occur in about 1 week to reevaluate whether relapse criteria are still met. 2. Patient discontinues for "Lost to Follow-up" after a visit in which he or she met Definition 1 criteria (a&b). 3. Patient begins a prohibited drug (whether a study investigator or outside source prescribed) to treat worsening symptoms of irritability of autistic disorder after a visit where patient met Definition 1 criteria (a&b). 4. Patient discontinues due to hospitalization for worsening symptoms of irritability or due to lack of efficacy based on investigator's assessment. |
From end of Phase 1 (Date of randomization) to Week 16 of Phase 2 and end of treatment
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Adjusted Mean Change From Baseline to Week 16 on the Aberrant Behavior Checklist Irritability (ABC-I) Subscale Score (Last Observation Carried Forward [LOCF])
Tidsramme: From Baseline (end of Phase 1) to Week 16 of Phase 2
|
ABC is an informant-based checklist used to assess and classify problem behaviors of children and adolescents with mental retardation. The 58 items are rated on a 4-point scale (0=not at all a problem to 3=the problem is severe in degree), and resolve into 5 subscales: 1) irritability, agitation; 2) lethargy, social withdrawal; 3) stereotypic behavior; 4) hyperactivity, noncompliance; and 5) inappropriate speech. The ABC can be completed by parents, special educators, psychologists, direct caregivers, nurses, and others knowing the participant. Psychometric assessment of the ABC indicates that its subscales have high internal consistency, adequate reliability, and established validity. The ABC-I Subscale Score ranges from 0 to 45, with a negative change in score signifying improvement. LOCF data set includes data recorded at a given visit or, if no observation was recorded at that visit, data carried forward from the prior visit. chg=change; BL=baseline; APR=aripiprazole; vs=versus. |
From Baseline (end of Phase 1) to Week 16 of Phase 2
|
|
Change From Baseline in Mean Clinical Global Impression Improvement (CGI-I) Scale Score at Week 16 (Last Observation Carried Forward [LOCF])
Tidsramme: From Baseline (end of Phase 1) to Week 16 of Phase 2
|
CG-I rating scale permits global evaluation of patient's improvement over time. At baseline (BL), CGI Severity of Illness assessment is performed, in which the clinician rates severity of patient's condition on a 7-point scale ranging from 1=no symptoms to 7=very severe symptoms. Higher total score=worse symptoms. At subsequent visits, clinician assesses patient's improvement relative to symptoms at baseline on CGI-I 7-point scale ranging from 1=very much improved to 7=very much worse. Since the drug targets irritability symptoms, the CGI focuses on severity of irritability secondary to autistic disorder. Lower score=more improved symptoms. LOCF data set includes data recorded at a given visit or, if nothing recorded, data areccarried forward from the prior visit. For secondary endpoints (endpt), hierarchical testing was used to keep overall experiment-wise type I error rate to <=0.05. diff=difference; IS=irritability scale; PA=primary analysis; signif=significance/significantly. |
From Baseline (end of Phase 1) to Week 16 of Phase 2
|
|
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), and Adverse Events (AEs) Leading to Discontinuation During Phase 1
Tidsramme: Up to 26 weeks
|
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. |
Up to 26 weeks
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation, and Treatment-related AEs During Phase 2
Tidsramme: Weekly from Weeks 1 through 16 (end of treatment) of Phase 2
|
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug. |
Weekly from Weeks 1 through 16 (end of treatment) of Phase 2
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Publikationer og nyttige links
Generelle publikationer
- Findling RL, Mankoski R, Timko K, Lears K, McCartney T, McQuade RD, Eudicone JM, Amatniek J, Marcus RN, Sheehan JJ. A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder. J Clin Psychiatry. 2014 Jan;75(1):22-30. doi: 10.4088/jcp.13m08500.
- Iffland M, Livingstone N, Jorgensen M, Hazell P, Gillies D. Pharmacological intervention for irritability, aggression, and self-injury in autism spectrum disorder (ASD). Cochrane Database Syst Rev. 2023 Oct 9;10(10):CD011769. doi: 10.1002/14651858.CD011769.pub2.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Anslået)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- CN138-603
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .